Comments on "Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine" by , J Neuroimmunol.
作者信息
Caravagna Céline
机构信息
F.M. Kirby Neurobiology Center, Boston Children's Hospital, Departments of Neurology and Ophthalmology, Harvard Medical School, Boston, MA, USA.
出版信息
J Neuroimmunol. 2022 Jan 15;362:577780. doi: 10.1016/j.jneuroim.2021.577780. Epub 2021 Nov 18.
Abstract
摘要
相似文献
1
Comments on "Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine" by , J Neuroimmunol.对[作者姓名]发表于《神经免疫学杂志》的《辉瑞 - 生物科技公司新冠疫苗接种后多发性硬化症的初始临床表现》的评论
J Neuroimmunol. 2022 Jan 15;362:577780. doi: 10.1016/j.jneuroim.2021.577780. Epub 2021 Nov 18.
2
First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.接种辉瑞-生物科技公司新冠疫苗后多发性硬化症的首发表现。
J Neurol. 2022 Jan;269(1):55-58. doi: 10.1007/s00415-021-10648-w. Epub 2021 Jun 11.
3
Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.接种辉瑞-生物科技公司的 COVID-19 疫苗后多发性硬化症的初始临床表现。
J Neuroimmunol. 2021 Dec 15;361:577755. doi: 10.1016/j.jneuroim.2021.577755. Epub 2021 Oct 20.
4
Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022.美国 2022 年 6 月关于在 6 个月至 5 岁儿童中使用 Moderna 和辉瑞-BioNTech COVID-19 疫苗的免疫实践咨询委员会临时建议。
MMWR Morb Mortal Wkly Rep. 2022 Jul 1;71(26):859-868. doi: 10.15585/mmwr.mm7126e2.
5
Considerations in Pfizer-BioNTech COVID-19 vaccine preparation in clinic: Quality vs quantity.在临床中考虑辉瑞-生物科技公司 COVID-19 疫苗准备工作：质量与数量。
Am J Health Syst Pharm. 2022 Feb 18;79(5):325-327. doi: 10.1093/ajhp/zxab388.
6
Finally, an FDA Approval for an Immunization Against COVID-19: Hope on the Horizon.终于，COVID-19 疫苗获得 FDA 批准：曙光在望。
Ann Pharmacother. 2022 Sep;56(9):1058-1064. doi: 10.1177/10600280211058387. Epub 2022 Jan 10.
7
Three cases of vesiculobullous non-IgE-mediated cutaneous reactions to tozinameran (Pfizer-BioNTech COVID-19 vaccine).三例对托珠单抗（辉瑞-生物科技新冠疫苗）的非IgE介导的水疱大疱性皮肤反应
J Eur Acad Dermatol Venereol. 2021 Dec;35(12):e855-e857. doi: 10.1111/jdv.17581. Epub 2021 Aug 16.
8
Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.辉瑞/生物科技和牛津/阿斯利康疫苗对沙特阿拉伯全国疫苗接种运动中真实环境下 COVID-19 发病率和死亡率的影响。
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7185-7191. doi: 10.26355/eurrev_202111_27271.
9
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗：辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
10
Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.美国五家退伍军人事务医疗中心 2021 年 2 月 1 日至 9 月 30 日期间住院退伍军人中 Moderna 和辉瑞-BioNTech COVID-19 疫苗的有效性和抗体反应比较。
MMWR Morb Mortal Wkly Rep. 2021 Dec 10;70(49):1700-1705. doi: 10.15585/mmwr.mm7049a2.
本文引用的文献
1
Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.接种辉瑞-生物科技公司的 COVID-19 疫苗后多发性硬化症的初始临床表现。
J Neuroimmunol. 2021 Dec 15;361:577755. doi: 10.1016/j.jneuroim.2021.577755. Epub 2021 Oct 20.
Zotero 插件